Specify a stock or a cryptocurrency in the search bar to get a summary
Evelo Biosciences Inc
EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Address: 620 Memorial Drive, Cambridge, MA, United States, 02139
Analytics
WallStreet Target Price
10 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EVLO
Dividend Analytics EVLO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EVLO
Stock Valuation EVLO
Financials EVLO
Results | 2019 | Dynamics |